A new drug being studied for the treatment of muscle degenerating diseases has shown promising results. According to a study published today in the British Journal of Pharmacology, Debio 025 is as effective as current drugs but, crucially, does not cause unwanted immunosuppressive effects. Bethlem Myopathy and Ullrich Congenital Muscular...
treatment News
WORCESTER, Mass. – Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted the Company’s...
WORCESTER, Mass. — Mustang Bio, Inc. (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced Phase 1 clinical data were published in Nature Medicine that demonstrated the promising safety and...
Dar es Salaam — The President of Zanzibar, Dr Hussein Mwinyi, has ordered state institutions to incorporate rare disease treatment in the health policy so that children facing such health issues can receive specialised care, particularly oxygen. Dr Mwinyi made the statement on Tuesday evening when he spoke to delegates...
BALTIMORE – MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,096,933 titled “Method of Treating Disorders...
MEDFORD, Mass. – Myrobalan Therapeutics, a biotechnology company developing potent, selective, and brain-penetrant oral small-molecule therapies to restore brain function, today announced a grant of over $850,000 from the National Multiple Sclerosis Society to support the preclinical and translational development of MRO-002, a G-protein-coupled receptor 17 (GPR17) antagonist, for the...
NEW YORK, NY — Myrtelle Inc. (“Myrtelle” or the “Company), a pioneering clinical-stage gene therapy company developing transformative treatments for neurodegenerative diseases, today announced the publication of interim results from its Phase 1/2 clinical trial of rAAV-Olig001-ASPA (MYR-101) in Nature Medicine. The published article, entitled, “Oligodendrocyte-targeted adeno-associated virus gene therapy for Canavan disease...
NEW YORK, NY — Myrtelle Inc. (“Myrtelle” or the “Company”), a pioneering clinical-stage gene therapy company dedicated to revolutionizing treatment for neurodegenerative diseases, today announced the official launch of commercial-stage manufacturing for its first-in-class oligotrophic recombinant adeno-associated virus (rAAV) gene therapy product, developed specifically for Canavan disease (CD). This landmark achievement propels...
NEW YORK, NY — Myrtelle Inc. (“Myrtelle” or the “Company), a pioneering clinical-stage gene therapy company developing transformative treatments for neurodegenerative diseases, today announced the publication of interim results from its Phase 1/2 clinical trial of rAAV-Olig001-ASPA (MYR-101) in Nature Medicine. The published article, entitled, “Oligodendrocyte-targeted adeno-associated virus gene therapy for Canavan disease in children: a phase 1/2...
NEW YORK, NY — Myrtelle, Inc., a clinical-stage gene therapy company selected by the FDA for the START Pilot Program and focused on developing treatments for neurodegenerative diseases, today announced its participation in the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting where clinical trial data from its...